ArticleCancers2024
Breast Cancer Patient's Outcomes after Neoadjuvant Chemotherapy and Surgery at 5 and 10 Years for Stage II-III Disease.
Abstract read
In one paragraph
Article in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Development and evaluation of clinical models based on ultrasound, serum CA153 and molecular subtype in predicting the efficacy of neoadjuvant chemotherapy in breast cancer.Oncology letters · 2026Article
- Article
- Germline Mutations Related to Complete Remission After Neoadjuvant Chemotherapy in Patients With Triple-negative Breast Cancer.Journal of breast cancer · 2026Article
- Predictive risk factors of recurrence in breast cancer after neoadjuvant treatment: the NEORISK study.Future oncology (London, England) · 2025Article
- A population‑based propensity score matching analysis of neoadjuvant compared to adjuvant chemotherapy in luminal breast cancer.Scientific reports · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
32 authors.
Catalina FaloMultidisciplinary Breast Cancer Unit, Department of Medical Oncology, Institut Català d'Oncologia, 08908 Barcelona, Spain.
Juan AzcarateMultidisciplinary Breast Cancer Unit, Department of Pathology, Hospital Universitari Bellvitge, 08907 Barcelona, Spain.
Sergi Fernandez-GonzalezInstituto de Investigación Biomédica de Bellvitge (IDIBELL), 08908 Barcelona, Spain.
Xavier PerezInformation and Data Analysis Department, Institut Català d'Oncologia, Bellvitge Research Institute, 08908 Barcelona, Spain.
Ana PetitInstituto de Investigación Biomédica de Bellvitge (IDIBELL), 08908 Barcelona, Spain.
Héctor PerezInstituto de Investigación Biomédica de Bellvitge (IDIBELL), 08908 Barcelona, Spain.ORCID 0000-0002-9756-5088
Andrea VethencourtMultidisciplinary Breast Cancer Unit, Department of Medical Oncology, Institut Català d'Oncologia, 08908 Barcelona, Spain.
Silvia VazquezMultidisciplinary Breast Cancer Unit, Department of Medical Oncology, Institut Català d'Oncologia, 08908 Barcelona, Spain.
Maria LaplanaInstituto de Investigación Biomédica de Bellvitge (IDIBELL), 08908 Barcelona, Spain.ORCID 0000-0001-9826-9494
Miriam AlesMultidisciplinary Breast Cancer Unit, Department of Medical Oncology, Institut Català d'Oncologia, 08908 Barcelona, Spain.
Agostina StradellaMultidisciplinary Breast Cancer Unit, Department of Medical Oncology, Institut Català d'Oncologia, 08908 Barcelona, Spain.
Bartomeu FullanaMultidisciplinary Breast Cancer Unit, Department of Medical Oncology, Institut Català d'Oncologia, 08908 Barcelona, Spain.
Maria J PlaInstituto de Investigación Biomédica de Bellvitge (IDIBELL), 08908 Barcelona, Spain.ORCID 0000-0001-7119-4031
Anna GumàInstituto de Investigación Biomédica de Bellvitge (IDIBELL), 08908 Barcelona, Spain.
Raul OrtegaInstituto de Investigación Biomédica de Bellvitge (IDIBELL), 08908 Barcelona, Spain.
Mar VarelaInstituto de Investigación Biomédica de Bellvitge (IDIBELL), 08908 Barcelona, Spain.
Diana PérezMultidisciplinary Breast Cancer Unit, Department of Reparative Surgery, Hospital Universitari Bellvitge, 08907 Barcelona, Spain.
Jose Luis PontonInformation and Data Analysis Department, Institut Català d'Oncologia, Bellvitge Research Institute, 08908 Barcelona, Spain.
Sara CoboMultidisciplinary Breast Cancer Unit, Department of Pharmacy, Hospital Universitari Bellvitge, 08907 Barcelona, Spain.
Ana BenitezMultidisciplinary Breast Cancer Unit, Department of Nuclear Medicine, Hospital Universitari Bellvitge, 08907 Barcelona, Spain.ORCID 0000-0001-8258-5564
Miriam CamposMultidisciplinary Breast Cancer Unit, Department of Gynecology, Hospital Universitari Bellvitge, 08907 Barcelona, Spain.ORCID 0009-0000-3112-7854
Adela FernándezMultidisciplinary Breast Cancer Unit, Department of Medical Oncology, Institut Català d'Oncologia, 08908 Barcelona, Spain.
Rafael VillanuevaMultidisciplinary Breast Cancer Unit, Department of Medical Oncology, Institut Català d'Oncologia, 08908 Barcelona, Spain.
Veronica ObadiaMultidisciplinary Breast Cancer Unit, Department of Medical Oncology, Institut Català d'Oncologia, 08908 Barcelona, Spain.
Sabela RecaldeMultidisciplinary Breast Cancer Unit, Department of Medical Oncology, Institut Català d'Oncologia, 08908 Barcelona, Spain.
Teresa Soler-MonsóMultidisciplinary Breast Cancer Unit, Department of Pathology, Hospital Universitari Bellvitge, 08907 Barcelona, Spain.
Ana Lopez-OjedaMultidisciplinary Breast Cancer Unit, Department of Reparative Surgery, Hospital Universitari Bellvitge, 08907 Barcelona, Spain.
Evelyn MartinezInstituto de Investigación Biomédica de Bellvitge (IDIBELL), 08908 Barcelona, Spain.
Jordi PonceInstituto de Investigación Biomédica de Bellvitge (IDIBELL), 08908 Barcelona, Spain.ORCID 0000-0002-0613-2261
Sonia PernasMultidisciplinary Breast Cancer Unit, Department of Medical Oncology, Institut Català d'Oncologia, 08908 Barcelona, Spain.ORCID 0000-0002-1485-5080
Miguel Gil-GilMultidisciplinary Breast Cancer Unit, Department of Medical Oncology, Institut Català d'Oncologia, 08908 Barcelona, Spain.ORCID 0000-0003-1380-2718
Amparo Garcia-TejedorInstituto de Investigación Biomédica de Bellvitge (IDIBELL), 08908 Barcelona, Spain.ORCID 0000-0003-3398-0570
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
breast cancerneoadjuvant chemotherapyprognostic factorssurvivalwell-informed decision making
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.